Apellis Pharmaceuticals Inc.（股票代码：APLS）今日盘中大涨14.16%，引起市场广泛关注。该公司最新发布的季度财报显示，其业绩表现优于分析师预期，成为推动股价上涨的主要因素。
根据公司公布的财报，截至6月30日的季度调整后每股亏损为0.33美元，明显优于分析师平均预期的0.48美元亏损。尽管当季营收为1.7849亿美元，同比下降10.6%，略低于分析师预期的1.8852亿美元，但投资者似乎更为看重公司在控制成本方面取得的进展。值得注意的是，尽管本季度股价上涨了9.8%，该公司股价今年迄今仍下跌了40.5%。
分析师对Apellis Pharmaceuticals保持乐观态度。目前，分析师对该公司股票的平均评级为"买入"，其中13个评级为"强烈买入"或"买入"，9个为"持有"，没有"卖出"或"强烈卖出"评级。华尔街给予该公司12个月目标价中位数为29.00美元，较上一交易日收盘价19.00美元高出约34.5%。这一积极展望可能进一步推动了投资者的买入热情。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.